Can Abilify Cause Tremor?
Yes, aripiprazole (Abilify) can cause tremor, though it is less likely to cause extrapyramidal symptoms including tremor compared to typical antipsychotics and some other atypical antipsychotics.
Evidence from FDA Drug Labeling
The FDA-approved drug label for Abilify explicitly lists tremor as a documented adverse effect. In overdose cases, tremor is reported as one of the common adverse reactions (occurring in at least 5% of overdose cases) 1. Additionally, the label documents tremor occurring in clinical contexts, confirming this as a recognized side effect of the medication 1.
Clinical Guidelines and Comparative Risk
Aripiprazole has a notably lower risk profile for extrapyramidal symptoms (EPS) compared to other antipsychotics. Multiple clinical guidelines consistently classify aripiprazole as having minimal propensity for causing EPS:
- The 2018 ESMO delirium guidelines specifically note that aripiprazole is "less likely to cause EPSEs" 2
- Pediatric emergency medicine guidelines from 2016 document that aripiprazole causes 0 milliseconds of QT prolongation and has favorable EPS profiles 3
However, tremor can still occur as part of drug-induced Parkinsonism syndrome, which includes bradykinesia, tremors, and rigidity resulting from antidopaminergic effects 4, 3.
Research Evidence on Tremor Incidence
The actual incidence of tremor with aripiprazole varies by population and indication:
- A 2019 meta-analysis of aripiprazole for tic disorders in children found a risk ratio of 10.26 for tremor compared to placebo, indicating significantly elevated risk 5
- In autism spectrum disorder trials, tremor was identified as a notable side effect requiring consideration alongside weight gain, sedation, and drooling 6
- Case reports document tremor occurring even with low doses: a 2-year-old who ingested only 10 mg exhibited marked tremor persisting over 72 hours 7
- A 2014 review noted that extrapyramidal side effects such as tremor and akathisia "may be treatment limiting in some cases" 8
Clinical Context and Risk Factors
Tremor risk appears higher in certain populations:
- Young patients: Children and adolescents may be at higher risk for EPS than adults 4
- Drug-naive patients: Those newly initiated on antipsychotics face elevated risk 9
- Male gender and young age: These are established risk factors for dystonic reactions and other EPS 4, 9
The tremor typically manifests as part of drug-induced Parkinsonism, which can be difficult to differentiate from negative symptoms of the underlying psychiatric condition 4.
Management Approach
If tremor develops on aripiprazole:
- Verify the diagnosis: Distinguish drug-induced Parkinsonism from disease-related symptoms or akathisia
- Consider dose reduction: If clinically feasible and symptoms are controlled 4
- Add anticholinergic agents: Such as benztropine or trihexyphenidyl for symptomatic relief 4, 3
- Consider dopaminergic agonists: Amantadine may be helpful 4, 3
- Switch antipsychotics: If tremor is treatment-limiting, consider alternatives with even lower EPS risk
Important Caveats
- While aripiprazole has a favorable EPS profile relative to other antipsychotics, it is not EPS-free
- The partial dopamine agonist mechanism that reduces EPS risk does not eliminate it entirely
- Tremor may be dose-dependent and can occur even at low, introductory doses 10, 9
- Early recognition and intervention are critical, as prompt withdrawal or dose adjustment typically leads to symptom resolution 10